The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV.

被引：11
|
作者：
Wang-Gillam, Andrea
Chen, Li-Tzong
Li, Chung-Pin
Bodoky, Gyorgy
Dean, Andrew
Lee, Kyung-Hun
Cunningham, David
Hubner, Richard
Braiteh, Fadi S.
Pipas, J. Marc
Belanger, Bruce
de Jong, Floris A.
Mody, Purvi D.
Von Hoff, Daniel D.
Siveke, Jens T.
机构：
[1] Washington Univ, Sch Med St Louis, St Louis, MO USA
[2] Natl Inst Canc Res, Natl Hlth Res Inst, Tainan, Taiwan
[3] Taipei Vet Gen Hosp, Taipei, Taiwan
[4] Szent Laszlo Teaching Hosp, Budapest, Hungary
[5] St John God Hosp, Subiaco, WA, Australia
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Royal Marsden Hosp, Sutton, Surrey, England
[8] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[9] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[10] Merrimack Pharmaceut Inc, Cambridge, MA USA
[11] Shire GmbH, Zug, Switzerland
[12] Translat Genom Res Inst TGen, Phoenix, AZ USA
[13] HonorHealth, Phoenix, AZ USA
[14] Univ Hosp, West German Canc Ctr, Essen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15795
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15795
引用
收藏
页数：6
相关论文
共 36 条
  • [21] Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±-5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.
    Macarulla, Teresa Mercade
    Hubner, Richard
    Blanc, Jean-Frederic
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew Peter
    Yanshen, Shan
    Jameson, Gayle S.
    Lee, Kyung-Hun
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Braiteh, Fadi S.
    Cunningham, David
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    Mamlouk, Khalid Kevin
    de Jong, Floris A.
    Siveke, Jens T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [22] Effects of nanoliposomal irinotecan (nal-IRI;MM-398) ± 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy
    Siveke, J. T.
    Cubillo, A.
    Blanc, J. -F
    Melisi, D.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L. -T
    Becker, C.
    Mamlouk, K.
    Belanger, B.
    Yang, Y.
    de Jong, F.
    Hubner, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 259 - 259
  • [23] Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Siveke, Jens T.
    Hubner, Richard
    Macarulla, Teresa Mercade
    Wang-Gillam, Andrea
    Dean, Andrew Peter
    Blanc, Jean-Frederic
    Cunningham, David
    Mirakhur, Beloo
    Belanger, Bruce
    de Jong, Floris A.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [24] Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
    Chen, L-T.
    Macarulla Mercade, T.
    Lee, K-H.
    Lakatos, G.
    Wang-Gillam, A.
    Mirakhur, B.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Macarulla, Teresa Mercade
    Siveke, Jens T.
    Dean, Andrew Peter
    Hubner, Richard
    Blanc, Jean-Frederic
    Cunningham, David
    Chen, Li-Tzong
    Mirakhur, Beloo
    Chen, Jie
    de Jong, Floris A.
    Wang-Gillam, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [26] Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study
    Melisi, D.
    Melisi, D.
    Siveke, J. T.
    Blanc, J.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L.
    Becker, C.
    Mamlouk, K.
    De Jong, F.
    Hubner, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Chen Li-Tzong
    Andrea, Wang-Gillam
    Shan Yan-Shen
    Teresa, Macarulla
    Jean-Frederic, Blanc
    Richard, Hubner
    Chiu Chang-Fang
    Gilberto, Schwartsmann
    Jens, Siveke
    Marc, Pipas J.
    Bruce, Belanger
    Floris, de Jong
    Khalid, Mamlouk
    Daniel, Von Hoff
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] A phase 1/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC).
    Dean, Andrew Peter
    Wainberg, Zev A.
    Ramanathan, Ramesh K.
    Boland, Patrick McKay
    Mody, Kabir
    Zhang, Bin
    Belanger, Bruce
    de Jong, Floris A.
    Braun, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/IN in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.
    Chen, Li-Tzong
    Siveke, Jens T.
    Wang-Gillam, Andrea
    Hubner, Richard
    Pant, Shubham
    Dragovich, Tomislav
    Chung, Vincent M.
    Chang, David Z.
    Ross, Paul J.
    Cooray, Prasad
    Tebbutt, Niall C.
    Franke, Fabio A.
    Belanger, Bruce
    Dhindsa, Navreet
    de Jong, Floris
    Mamlouk, Khalid
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine
    Hubner, R.
    Cubillo, A.
    Blanc, J. -F.
    Melisi, D.
    Von Hoff, D.
    Wang-Gillam, A.
    Chen, L. -T.
    Becker, C.
    Mamlouk, K.
    Belanger, B.
    Yang, Y.
    De Jong, F.
    Siveke, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 119 - 119
1234